• Would clinical inertia be reduced? |
• Would there be a delay in deterioration of glycemic control? Better durability? Better β-cell function over time? Does the approach address pathophysiology better? |
• Does it allow for assessing individual response? |
• Are the costs appropriate? Would this approach result in cost savings and reduction in complications over time? |
• Is the risk-to-benefit ratio acceptable? |
• Would it improve unmet clinical needs, such as weight gain, hypoglycemia, etc.? |
• Would adherence/compliance remain issues? |
• Would clinical inertia be reduced? |
• Would there be a delay in deterioration of glycemic control? Better durability? Better β-cell function over time? Does the approach address pathophysiology better? |
• Does it allow for assessing individual response? |
• Are the costs appropriate? Would this approach result in cost savings and reduction in complications over time? |
• Is the risk-to-benefit ratio acceptable? |
• Would it improve unmet clinical needs, such as weight gain, hypoglycemia, etc.? |
• Would adherence/compliance remain issues? |